Esophageal Cancer – Pipeline Review, H2 2020
Esophageal Cancer – Pipeline Review, H2 2020, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.
Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.
Esophageal Cancer – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 12, 77, 91, 7, 29, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 6, 4 and 3 molecules, respectively.
Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).
– The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology)
Reasons to Buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Esophageal Cancer (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Esophageal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Advanced Accelerator Applications SA
Advenchen Laboratories LLC
AIMM Therapeutics BV
AMI Onco Theranostics LLC
Anhui Anke Biotechnology (Group) Co Ltd
Anhui Kedgene Biotechnology Co Ltd
Aprea Therapeutics Inc
Arog Pharmaceuticals Inc
Ascenta Therapeutics Inc
Ascentage Pharma Group International
Astellas Pharma Inc
AVEO Pharmaceuticals Inc
Bicycle Therapeutics Plc
BioMed Valley Discoveries Inc
BioStar Pharmaceuticals Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Celldex Therapeutics Inc
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chi Cheung (Shanghai) Biomedical Co Ltd
Chugai Pharmaceutical Co Ltd
Cotinga Pharmaceuticals Inc
CStone Pharmaceuticals Co Ltd
Cyclacel Pharmaceuticals Inc
CytomX Therapeutics Inc
DAE HWA Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Delta-Fly Pharma Inc
Dragonboat Biopharmaceutical (Shanghai)Co Ltd
Dragonfly Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Genentech USA Inc
GLG Pharma SA
Gossamer Bio Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangzhou Anjie Biomedical Technology Co Ltd
Guangzhou Saliai Stemcell Science and Technology Co Ltd
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
HEC Pharm Co Ltd
Hualan Biological Engineering Inc
Hutchison MediPharma Ltd
Idera Pharmaceuticals Inc
ImmuneSensor Therapeutics Inc
Immvira Co Ltd
Innovent Biologics Inc
Inovio Pharmaceuticals Inc
Jacobio Pharmaceuticals Co Ltd
JenKem Technology Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Simcere Pharmaceutical Co Ltd
Johnson & Johnson
Kitov Pharma Ltd
Leap Therapeutics Inc
LEXEO Therapeutics LLC
LIfT BioSciences Ltd
Medical Guidance Systems LLC
Merck & Co Inc
Mereo Biopharma Group Plc
Modra Pharmaceuticals BV
Molecular Templates Inc
Myeloid Therapeutics Inc
New B Innovation Ltd
NGM Biopharmaceuticals Inc
Novita Pharmaceuticals Inc
OBI Pharma Inc
Omnitura Therapeutics Inc
Oncolys BioPharma Inc
Onconova Therapeutics Inc
Ono Pharmaceutical Co Ltd
PDS Biotechnology Corp
Pieris Pharmaceuticals Inc
Puma Biotechnology Inc
Quadriga BioSciences Inc
Rafael Pharmaceuticals Inc
Rakuten Medical Inc
RAPT Therapeutics Inc
RaQualia Pharma Inc
Revolution Medicines Inc
Rhizen Pharmaceuticals SA
Scancell Holdings Plc
Seattle Genetics Inc
Seven and Eight Biopharmaceuticals Corp
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Junshi Bioscience Co Ltd
Shanghai Keqi Pharmaceutical Technology Co Ltd
Shanghai Miracogen Inc
Shenyang Dongxing Pharmaceutical Co Ltd
Shenzhen BinDeBio Ltd
Shenzhen Hornetcorn Bio-technology Company Ltd
Shenzhen NeoCura Biotechnology Corp
Shionogi & Co Ltd
Sino Biopharmaceutical Ltd
Smerud Medical Research International AS
Soricimed Biopharma Inc
Sorrento Therapeutics Inc
Starpharma Holdings Ltd
Steba Biotech SA
Stemirna Therapeutics Inc
Supratek Pharma Inc
Sutro Biopharma Inc
Suzhou Sinovent Pharmaceuticals Co Ltd
Suzhou Stainwei Biotech Inc
TAE Life Sciences LLC
Taiho Oncology Inc
Takara Bio Inc
Telix Pharmaceuticals Ltd
Tessa Therapeutics Ltd
Themis Bioscience GmbH
TOT Biopharm Co Ltd
Transgene Biotek Ltd
Turnstone Biologics Inc
Tyg Oncology Ltd
Viral Gene Inc
VM Discovery Inc
Xiangxue Life Sciences
XuanZhu Pharma Co Ltd
Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
For queries regarding this report: https://www.researchbymarkets.com/sample-request/645856